Tesamorelin dosing chart (mg to units)
Tesamorelin's 2 mg vial amount comes from a prescribing-label source in PinPoint's library. Its description identifies a stabilized GHRH analog, and the peptide record carries an FDA-approved research-status tag. The amount table translates portions of that 2 mg total into volume. The cited prescribing information is for Egrifta SV.
Vial concentration
Water mL is treated as final solution mL in these columns.
| Vial contents | 1 mL water | 2 mL water | 3 mL water |
|---|---|---|---|
| 2 mg | 2 mg/mL50 U-100 units per mg | 1 mg/mL100 U-100 units per mg | 0.6667 mg/mL150 U-100 units per mg |
Vial source: PinPoint/Data/CompoundLibrary.swift, line 765, the Tesamorelin entry. One documented amount is available.
Amount to units
Example amounts (arithmetic only, not doses).
| Amount (mg) | 2 mg + 1 mL | 2 mg + 2 mL | 2 mg + 3 mL |
|---|---|---|---|
| 0.04 mg | 2 units | 4 units | 6 units |
| 0.1 mg | 5 units | 10 units | 15 units |
| 0.2 mg | 10 units | 20 units | 30 units |
| 0.4 mg | 20 units | 40 units | 60 units |
| 1 mg | 50 units | 100 units | 150 unitsover one syringe |
Cited amounts
| Amount (mg) and source context | Frequency as stated | Route as stated | 2 mg + 1 mL | 2 mg + 2 mL | 2 mg + 3 mL | Source |
|---|---|---|---|---|---|---|
| 1.4 mgSpecific 2 mg/vial formulation; source preparation is 0.5 mL with a 0.35 mL administration, distinct from these arithmetic columns. | Once daily | Subcutaneous | 70 units | 140 unitsover one syringe | 210 unitsover one syringe | Tesamorelin prescribing information (Egrifta SV)Regulatory labelRetrieved 2026-10-05 |
How to read this chart
Find the concentration column. Divide the amount by that concentration. Multiply the mL value by 100 for U-100 units. Match the amount units before dividing.
units = amount ÷ (vial mg ÷ water mL) × 100
Amount and volume
One mg equals 1,000 mcg; 100 U-100 units equals 1 mL. Concentration connects amount to volume. Read the full conversion guide.
Nine minutes is an elimination parameter
PinPoint stores 0.15 hours as tesamorelin's half-life, equivalent to nine minutes. The source annotation ties the reference to prescribing-label information. This short value sets the elimination timescale of the base model; it is not a calendar interval for logging. The common-frequency field separately reads Once daily. A timestamp therefore places a short modeled event within a much longer daily record. The app can retain both the day-level sequence and the more detailed clock time without treating those two scales as interchangeable.
Why the peak-time field is a different number
The tesamorelin entry uses a 0.25-hour peak-time parameter, or 15 minutes, alongside a bioavailability coefficient of 0.04, or 4%. The peak input is longer than the stored nine-minute half-life. That arrangement reflects the separate roles of absorption and elimination in the model; a half-life is not a countdown from logging to the peak. These values describe the base compound profile, while an individual log supplies the event's amount and timestamp. None of the three model fields is a concentration in mg per mL.
Subcutaneous context and a label-based package
Subcutaneous is the route listed for tesamorelin, and the library uses a compounded-vial delivery form for its generic record. The package citation specifically documents 2 mg in a single-dose vial. In this collection, that label-based amount stands apart from the many vial totals obtained from supplier catalogs. The research-status tag, delivery-form field, and package citation each describe a different aspect of the entry. Reading them together explains why this page uses a 2 mg reference instead of borrowing a larger peptide vial size.
The one-milligram-per-milliliter column
When 2 mg is represented in a final volume of 2 mL, concentration is exactly 1 mg per mL. The tesamorelin example rows of 0.04, 0.1, 0.2, 0.4, and 1 mg then occupy those same numerical amounts in mL. For instance, 0.2 mg becomes 0.2 mL, corresponding to 20 U-100 units. This numerical match belongs to that one concentration. At a 1 mL total volume, the 0.2 mg portion is 0.1 mL; at 3 mL total, it is 0.3 mL.
Questions about the conversion
What concentration is Tesamorelin at 2 mg in 1 mL?
2 mg divided by 1 mL is 2 mg per mL. That volume spans 100 U-100 syringe units.
How does 2 mL change the concentration of this Tesamorelin vial?
2 mg divided by 2 mL is 1 mg per mL, half the concentration in the 1 mL column.
What does the 3 mL column mean for Tesamorelin?
2 mg divided by 3 mL is approximately 0.6667 mg per mL. The full 3 mL volume corresponds to 300 U-100 units.
How many units is 0.2 mg of Tesamorelin from this vial in 2 mL?
0.2 mg divided by 1 mg per mL is 0.2 mL, or 20 U-100 units.
How many units is the 1.4 mg cited amount of Tesamorelin from a 2 mg vial in 2 mL?
The arithmetic is 1.4 mg ÷ 1 mg/mL × 100 = 140 U-100 units (1.4 mL). The amount is cited in Tesamorelin prescribing information (Egrifta SV). Specific 2 mg/vial formulation; source preparation is 0.5 mL with a 0.35 mL administration, distinct from these arithmetic columns. This exceeds one 1 mL syringe.
Track your calculations in the app
PinPoint for iOS brings vial setup, unit conversion, dose logs, site rotation, and protocol tracking together. Enter vial size and water volume for concentration and syringe units, then log injections with compound, dose, site, and pain level.
Get PinPoint on the App Store